ROLE OF CHEMOTHERAPY IN THE CURRENT TREATMENT OF METASTATIC MELANOMA
Author(s)
Klink AJ1, Nabhan C2, Feinberg BA1
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA
OBJECTIVES: With recent approvals of immuno-oncology (IO) and targeted therapies (TT) that demonstrated improved efficacy versus chemotherapy comparator for metastatic melanoma (MM), the role of chemotherapy for this disease is less well defined. We aimed to describe current treatment patterns for MM in real-world. METHODS: A retrospective observational study was conducted using a large US claims database to identify adult patients with ≥1 claim of melanoma and ≥1 claim of metastasis between 1/1/2015 and 3/31/2017. Patients included had both pharmacy and medical enrollment with ≥3 months follow-up from start of first line (1L) metastatic treatment. Patients with a second primary cancer diagnosis, in a clinical trial, pregnant, or diagnosed with HIV/AIDS during the study were excluded. Patients were classified by 1L treatment: PD-1 inhibitor, ipilimumab, ipilimumab + nivolumab (I/N) combination, BRAF/MEK monotherapy, BRAF/MEK combination therapy, or chemotherapy. Treatment patterns were summarized using descriptive statistics for each treatment group by year. RESULTS: CONCLUSIONS: Despite the introduction of IO and TT for the treatment of MM, almost one third of patients are treated with chemotherapy in 1L and 2L. Improved overall survival with IO and TT warrants further research to understand use of chemotherapy in melanoma.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN261
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior, Treatment Patterns and Guidelines
Disease
Oncology